You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Insulet Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Insulet Company Info
Insulet makes the leading wearable, tubeless insulin pump for diabetics.
News & Analysis
Investors are cheering the company's strong Q3 results.
The company is reportedly in discussions with Dexcom about a potential merger.
After some upsetting delays, the FDA has finally approved a key new product.
As the prevalence of diabetes has grown, these companies are looking for solutions.
Here’s why a company making an essential and widely popular insulin pump is a solid buy amidst the backdrop of the COVID-19 pandemic.
The COVID-19 pandemic is presenting a headwind, but Insulet's recurring-revenue-generating business model helps insulate it.
These four companies have tremendous growth potential going into 2020.
Shares of the tubeless insulin pump maker are also outperforming the market in 2020.
PODD earnings call for the period ending September 30, 2021.
PODD earnings call for the period ending June 30, 2021.
PODD earnings call for the period ending March 31, 2021.
PODD earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.